Pictet Asset Management (Switzerland)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$179M	Buy	2,063,810 +9,288	+0.5%	+$874K	0.21%	124
2023 Q1	$200M	Buy	2,054,522 +576,001	+39%	+$59.7M	0.25%	120
2022 Q4	$153M	Buy	1,478,521 +710,154	+92%	+$66.7M	0.22%	139
2022 Q3	$65.1M	Buy	768,367 +276,664	+56%	+$24.6M	0.1%	235
2022 Q2	$40.7M	Buy	491,703 +12,923	+3%	+$1.03M	0.06%	319
2022 Q1	$36.9M	Sell	478,780 -7,994	-2%	-$669K	0.04%	373
2021 Q4	$43M	Sell	486,774 -268,054	-36%	-$22.1M	0.04%	368
2021 Q3	$58.3M	Buy	+754,828	New	+$59.6M	0.06%	307

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s BMRN Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its BioMarin Pharmaceuticals (BMRN) stake by 0.45% in Q2 2023, buying an estimated $874K and bringing the position to 2,063,810 shares worth $179M. The position accounts for 0.21% of the portfolio, ranked #124.

Pictet Asset Management (Switzerland) first reported a position in BMRN in Q3 2021 and has held it in 8 quarters since. The position peaked at $200M in Q1 2023. 559 funds tracked by Wall St. Rank hold BMRN as of Q2 2023.

Pictet Asset Management (Switzerland) held 2,063,810 shares of BioMarin Pharmaceuticals worth $179M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 9,288 BioMarin Pharmaceuticals shares in Q2 2023, an estimated $874K.
BioMarin Pharmaceuticals made up 0.21% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #124 holding.
Pictet Asset Management (Switzerland) first reported a position in BioMarin Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s BioMarin Pharmaceuticals position peaked at $200M in Q1 2023.
559 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.